Lōkahi Therapeutics

Lōkahi Therapeutics is a pre-clinical stage biotechnology company dedicated to developing a new class of precision oncology medicines that target the control of protein synthesis. The company’s platform focuses on the eukaryotic translation initiation factor 4F (eIF4F) complex, which acts as a critical node for the translation of mRNAs involved in tumor survival, metastasis, and immune evasion. By selectively inhibiting this complex, Lōkahi aims to disrupt the production of oncogenic proteins that are otherwise difficult to target with traditional inhibitors. Their lead programs are currently in the pre-clinical stage, focusing on solid tumors that have developed resistance to current standards of care, including immunotherapies. Founded on research from NYU Langone Health, the company leverages deep expertise in RNA biology and translational control to address unmet needs in aggressive cancers.